a public good project by the
Synthesis
Company
of California

© 2026

Dahui Zhou | doi.page

0 works0 citations0 h-index

Dahui Zhou

Pfizer (United States)(US)First Affiliated Hospital of Bengbu Medical College(CN)

Publications by Year

Research Areas

HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Receptor Mechanisms and Signaling, Neurotransmitter Receptor Influence on Behavior, Coordination Chemistry and Organometallics

Most-Cited Works

→ Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates(2013)488 cited
→ Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design(2016)201 cited
→ Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)(2017)199 cited
→ Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading(2015)166 cited
→ Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery—Building chiral technology toolboxes(2007)102 cited
→ RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models(2016)99 cited

→ Enhanced chromatographic resolution of amine enantiomers as carbobenzyloxy derivatives in high-performance liquid chromatography and supercritical fluid chromatography(2005)

73 cited

→ Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy(2015)63 cited

→ Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT_1Aand Serotonin Transporter Affinity within a Class ofN-Aryloxyethylindolylalkylamines(2004)58 cited

→ Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity(2005)49 cited